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ALTHOUGH there has been progress in the development of 
combination chemotherapy regimens for patients with advanced 
bladder cancer there is a need for new active agents [l-3]. 
Methylglyoxal bis-guanylhydrazone (MGBG) is a polyamine 
biosynthesis inhibitor which induced complete remission in 
patients with transitional cell carcinoma of the bladder in phase 
I trials with the agent [4]. 
46 patients with advanced metastatic transitional cell carci- 
noma of the bladder were entered into a phase II trial. Eligibility 
criteria included: histologically confirmed, bidimensionally 
measurable metastatic transitional cell carcinoma of the bladder; 
only one previous systemic chemotherapy or immunotherapy 
regimen (up to two previous intravesical chemotherapy or 
immunotherapy regimens were acceptable); patients could have 
had radiotherapy if the disease had progressed (if measurable 
disease existed outside the previous radiation field); patients had 
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Table 1. Patients’ characteristics 
Entered 
Total eligible (1 patient had no measurable disease) 
M/F 
Median age in years (range) 





Radiation therapy + chemotherapy 
Chemotherapy* or immunotherapy 





Unknown (too early) 





Assumed no response 
No follow-up measurements 
Early death 



























*Methotrexate + vinblastine + doxorubicin + cisplatin. 
to have a SWOG performance status of 3 or less; white cells 
3.500/$ or more and platelets 100,000/~1 or more; serum creatin- 
ine 177 PrnoVl or less and serum bilirubin 34 pmol/l or less; and 
patients’ informed consent. 
MGBG was administered weekly at 600 mg/m* as an intra- 
venous infusion in 150 ml DSW or normal saline over 30 min or 
more. Dose escalations of 100 mg/m* were given if no toxicity 
was noted. Weekly doses were reduced by 100 mg/m* for severe 
(SWOG grade 3) toxicities. One course of therapy was delined 
as 4 weeks of MGBG. SWOG criteria were used to assess tumour 
response. 
45 of the 46 patients entered were eligible (Table 1). 1 patient 
had no measurable disease. 20 of the eligible patients (44%) had 
at least one or more courses. There were no complete or partial 
responses. The exact 95% confidence interval of 0 out of 45 is 
O-8%. 
Toxicities in the study consisted of grade 3 (severe) or greater 
nausea and vomiting in 16% ofpatients, with 2 patients requiring 
admission. Grade 3 diarrhoea occurred in 9% of patients (1 
admitted). 1 patient had grade 4 mucositis and 1 had a perforated 
diverticulum leading to death. Other grade 2 or greater toxicities 
included fatigue and weakness in 3 patients, hypoglycaemia in 
2, hypotension (under 90 mmHg systolic) in 2, weight loss in 4 
patients (1 lost 4.5 kg and 1 lost 7.7 kg), and anaemia in 8. 
Toxicities were so troublesome that 8 patients refused additional 
treatments (usually after only l-3 doses). 
Despite the protocol calling for failure on only one previous 
chemotherapeutic regimen it is clear the patient population was 
